.webp)
Key takeaways:
- The American Gastroenterological Association now recommends brain-gut behavior therapies, such as gut-directed hypnotherapy, and digital therapeutics as integral components of evidence-based IBS care.
- As a disorder of gut-brain interaction, IBS requires targeted interventions that address this mechanism directly for effective management.
- The AGA quality indicators, developed with the Rome Foundation, acknowledge limited access to qualified specialists and highlight digital therapeutics as a scalable, evidence-based adjunct.
- Clinically validated app-based gut-directed hypnotherapy, like Nerva, can help providers offer guideline-supported care while reducing cost and access barriers for patients.
The American Gastroenterological Association (AGA) now officially recommends brain–gut behavior therapies (BGBT), such as gut-directed hypnotherapy (GDH), and digital therapeutics as integral components of evidence-based IBS care.
This marks a significant shift, reaffirming what research has long demonstrated: as a disorder of gut-brain interaction, IBS requires targeted interventions that address this mechanism directly for effective management.
For healthcare providers, this update is particularly impactful as it strengthens the clinical validity of brain-gut behavior therapies while acknowledging the structural and logistical barriers that limit patient access.
